Definition, Phenotyping of Severe Asthma, Including Cluster Analysis

Area of Science:

• Pulmonology and Allergy
• Precision Medicine

Background:

• Severe asthma is defined by uncontrolled symptoms despite high-intensity treatment or loss of control during step-down therapy.
• Historically, asthma management relied on uniform high-dose corticosteroids, overlooking individual inflammatory states.
• The understanding of asthma pathogenesis evolved from allergic genesis to recognizing the role of eosinophils, particularly with advancements in monoclonal antibody therapies targeting interleukin 5.

Approach:

• Reviewing historical and current definitions of severe asthma phenotypes.
• Evaluating the limitations of cluster analysis algorithms in predicting inflammatory phenotypes and clinical applicability.
• Exploring the potential of omics data and biologic-treated patient cohorts for more promising cluster analyses.

Key Points:

• Phenotyping severe asthma has been challenging due to a scarcity of reliable biomarkers.
• Previous phenotyping approaches, including sputum eosinophil counts and cluster analysis, showed limited predictive value.
• The development of precision medicine necessitates identifying clinical or biological elements predictive of response to advanced therapies like biologics.

Conclusions:

• Current phenotyping methods for severe asthma are insufficient for guiding precise treatment strategies.
• Future research should focus on omics data and patient cohorts treated with biologics to develop predictive biomarkers.
• Advancing precision medicine in severe asthma requires overcoming the challenge of biomarker scarcity for effective patient stratification and targeted therapy.